Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
69 hedge funds and large institutions have $269M invested in Repare Therapeutics in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 22 closing their positions.
271% more call options, than puts
Call options by funds: $393K | Put options by funds: $106K
1.34% more ownership
Funds ownership: 86.13% → 87.47% (+1.3%)
9% less funds holding
Funds holding: 76 → 69 (-7)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
35% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 23
39% less capital invested
Capital invested by funds: $438M → $269M (-$169M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$17.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11.4M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.54M |
| 4 |
Morgan Stanley
New York
|
+$3.45M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$21.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13M |
| 3 |
BlackRock
New York
|
-$1.51M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.48M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.43M |
RPTX Hedge Fund Activity: Q4 2023 in Review
69 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q4 2023, worth a combined $269M — down 39% from $438M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of RPTX and 16 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 15 added.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $17.5M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $21.7M sold.
- 69 institutional investors held Repare Therapeutics (RPTX) as of Q4 2023, down from 76 in Q3 2023.
- Funds reported $269M of Repare Therapeutics stock for Q4 2023, down 39% quarter-over-quarter.
- 16 funds opened new Repare Therapeutics positions in Q4 2023 and 22 closed out, a net change of -6 holders.
- The largest Repare Therapeutics buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $17.5M added.
- The largest Repare Therapeutics seller in Q4 2023 was T. Rowe Price Investment Management, an estimated $21.7M sold.
Based on aggregated 13F filings for Q4 2023.